Objective To quantify bone marrow bcr/abl mRNA levels in imatinib mesylate treated Ph
chromosome positive chronic myeloid leukemia (CML) patients. Methods Serial monitoring …

We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …

Abstract 1726 With prolonged imatinib therapy, BCR-ABL transcript levels measured by RQ-
PCR assay show a progressive reduction, and some patients achieve complete molecular …

Introduction: Historically, many revolutionary advances in therapy for chronic myeloid
leukemia (CML) have been achieved over time, among them most important being imatinib …

Objective To monitor the expression patterns of bcr-abl in chronic myeloid leukemia (CML)
patients during treatment with imatinib mesylate and evaluate the detection of MRD by RQ …

Quantification of the BCR-ABL transcript is recommended to follow-up CML patients treated
by imatinib mesylate (IM). Results are expressed as a normalized copy number (NCN) of …

Imatinib mesylate has significantly improved the outcome of patients with CML. In the IRIS
trial, major molecular response (MMR), which is defined as the achievement of> or= 3 log …

6554 Background: Imatinib mesylate (STI571; Gleevec) is very effective in the therapy of
chronic phase chronic myeloid leukemia (CML). Early data suggests that the 800 mg of …

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the
Philadelphia chromosome, have drastically improved the outcomes for patients with chronic …

The optimal management of malignant haematological disorders depend on the degree of
tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for …